Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT.

Authors :: Adenis, Antoine
Piessen, Guillaume
Le Sourd, Samuel
Bogart, Emilie
Paumier, Amaury
Vendrely, Veronique
Glehen, Olivier
Dahan, Laetitia
Simmet, Victor
Bergeat, Damien
Samalin, Emmanuelle
Chauvenet, Marion
d'Journo, Xavier Benoit
Hiret, Sandrine
Gronnier, Caroline
Baty, Manon
Pannier, Diane
Veziant, Julie
Le Deley, Marie-Cecile
Mirabel, Xavier
Source :: Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p370-370, 1p
Publication Year :: 2023

Full Text Access

Tools